摘要
目的研究西洛他唑对行PCI术后非ST段抬高型心肌梗死(NSTEMI)患者血浆中金属基质蛋白酶(MMPs)浓度及左心室重构的影响。方法对2007年7月至2008年7月沈阳军区总医院行PCI的NSTEMI患者164例,分为西洛他唑治疗组及非西洛他唑治疗组。ELISA检测心肌梗死发病后2、4天、2、4周血浆中MMP-2、MMP-9的浓度。比较PCI术后6个月两组左室舒张末容积改变(ΔLVEDV)和左室射血分数的变化(ΔLVEF)。结果随访6个月结果显示,西洛他唑显著降低心肌梗死后ΔLVEDV及ΔLVEF的值(P<0.01)。西洛他唑显著性降低心肌梗死后4天、2周和4周的MMP-9及MMP-2浓度(P<0.01)。结论西洛他唑可以明显改善行PCI后的NSTEMI患者的左心室重构,其部分机制与其抑制血浆中MMP-2和MMP-9浓度有关。
Objective To investigate the effect of cilostazol on concentration of matrix metalloproteinases （MMPs） in plasma and on left ventricular remodeling in patients with non-ST segment elevation myocardial infarction （NSTEMI） after PCI. Methods 164 NSTEMI patients underwent PCI in the General Hospital of Shenyang Military Region during July of 2007 and July of 2008 were randomized into cilostazol and non-cilostazol group. Plasma MMP-2 and MMP-9 were assayed by ELISA at intervals （2d,4d,2w and 4w） after onset of NSTEMI. The serial changes of left ventricular end diastolic volume （ALVEDV） and left ventricular ejection fraction （LVEF） 6 months later after PCI were compared. Results Results of 6 months follow up indicated cilostazol decreased ALVEDV and ALVEF significantly after myocardial infarction （P 〈 0. 01 ）. MMP-2 and MMP-9 concentration were significantly decreased at 4 d,2w and 4w after NSTEMI （ P 〈 0. 01 ）. Conclusion Cilostazol may significantly improve LV remodeling in patients with NSTEMI after PCI, mechanism of which is partly related with MMP-2 and MMP-9 concentration inhibition.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2010年第7期636-637,共2页
Chinese Journal of Practical Internal Medicine
基金
辽宁省自然科学基金(项目编号20082074)
关键词
非ST段抬高型心肌梗死
西洛他唑
左心室重构
Non-ST elevation myocardial infarction
cilostazol
left ventricular remodeling
